MX2019001425A - Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea. - Google Patents

Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.

Info

Publication number
MX2019001425A
MX2019001425A MX2019001425A MX2019001425A MX2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A
Authority
MX
Mexico
Prior art keywords
compositions
treating
rosacea
preventing rosacea
composition
Prior art date
Application number
MX2019001425A
Other languages
English (en)
Inventor
Roye Olivier
Jacovella Jean
Jomard André
Original Assignee
Nestle Skin Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Skin Health Sa filed Critical Nestle Skin Health Sa
Publication of MX2019001425A publication Critical patent/MX2019001425A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición que comprende un vehículo farmacéuticamente aceptable, al menos un compuesto de la familia de la avermectina y al menos un compuesto antiinflamatorio no esteroideo. La presente invención proporciona, adicionalmente, tal composición para su uso en el tratamiento y/o la prevención de la rosácea.
MX2019001425A 2016-08-04 2017-08-04 Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea. MX2019001425A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306013 2016-08-04
PCT/EP2017/069809 WO2018024888A1 (en) 2016-08-04 2017-08-04 Compositions and the use thereof for treating or preventing rosacea

Publications (1)

Publication Number Publication Date
MX2019001425A true MX2019001425A (es) 2019-06-10

Family

ID=56618112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001425A MX2019001425A (es) 2016-08-04 2017-08-04 Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.

Country Status (10)

Country Link
US (1) US10874682B2 (es)
EP (1) EP3493795A1 (es)
JP (1) JP2019523291A (es)
KR (1) KR20190039735A (es)
CN (1) CN109789118B (es)
AU (1) AU2017305853B2 (es)
BR (1) BR112019002213A2 (es)
MX (1) MX2019001425A (es)
RU (1) RU2738932C2 (es)
WO (1) WO2018024888A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210052490A1 (en) * 2019-08-20 2021-02-25 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
RU2350333C3 (ru) 2003-04-24 2018-08-24 Галдерма С.А. Применение ивермектина для лечения дерматологических расстройств
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
FR2891460B1 (fr) * 2005-09-30 2010-07-30 Galderma Sa Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US8541022B2 (en) * 2008-06-02 2013-09-24 Galderma S.A. Method of treating burns using avermectin compound
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
PL2793874T3 (pl) * 2011-12-20 2017-06-30 Ectin Research Ab Synergistyczna kombinacja do inhibicji guza
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
US9233118B2 (en) * 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
WO2016069952A1 (en) * 2014-10-31 2016-05-06 Sreedhar Rao Rayudu Anti-acne composition and methods of use
WO2016096797A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses

Also Published As

Publication number Publication date
RU2738932C2 (ru) 2020-12-18
JP2019523291A (ja) 2019-08-22
AU2017305853B2 (en) 2023-04-13
US10874682B2 (en) 2020-12-29
EP3493795A1 (en) 2019-06-12
RU2019105758A (ru) 2020-09-04
US20190192545A1 (en) 2019-06-27
RU2019105758A3 (es) 2020-09-10
WO2018024888A8 (en) 2018-06-07
CN109789118B (zh) 2022-09-02
WO2018024888A1 (en) 2018-02-08
KR20190039735A (ko) 2019-04-15
AU2017305853A1 (en) 2019-01-31
BR112019002213A2 (pt) 2019-05-14
CN109789118A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12020500033A1 (en) Macrocyclic compounds and uses thereof
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
NZ722326A (en) Tricyclic compounds as anticancer agents
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2019009235A (es) Compuestos antifibroticos.
GB2543723A (en) Polyphenol compositions
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
UY37316A (es) Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
MX2018012193A (es) Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus.